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INTRODUCTION
Rabbits are common household pets in the United States 
and many European countries. The population of pet rab-
bits is estimated at several million and this number is 
thought to be rapidly increasing (1). Veterinarians can 
now expect to see rabbits routinely and be required to per-
form both routine and increasingly complex procedures 
on this species (2). Paralleling this trend is the increasing 
need to ensure adequate and reliable analgesia. Pain is 
probably under-treated in small animals, such as rabbits 
(3, 4), due to a lack of familiarity with the species, limited 
information about analgesic dose, efficacy and safety, and 
the difficulties associated with assessing pain and efficacy 
of pain management in rabbits (5). However, rabbits are 
likely to experience pain following trauma, surgery or dis-
ease and it is ethically and morally desirable to provide 
analgesia. 
Opioids are frequently used for management of moder-
ate to severe pain. Classical opioid drugs produce analgesia 
by binding to mu and/or kappa opioid receptors, although 
stimulation of these same receptors can result in adverse 
effects, including sedation, respiratory depression and re-
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ABST RACT
Pain is probably under-treated in animals, particularly in rabbits, due to a lack of familiarity with the species 
and limited information about analgesic dose, efficacy and safety. Tapentadol (TAP) is a novel opioid drug, 
with a proven efficacy and safety profile in humans, which could be useful as an analgesic in rabbits. In 
a clinical study, TAP was administered (5 mg/kg, IV) to seven male New Zealand White rabbits 5 min 
before anaesthetic induction with sevoflurane to perform orchiectomy. Monitoring of vital signs, including 
heart rate, electrocardiogram, respiratory rate, invasive blood pressure, oxygen saturation, righting reflex, 
palpebral reflex, jaw tone and tongue retraction, was performed throughout surgery. Pain was assessed for 
8 h following surgery, using previously validated parameters, physiological assessments and behavioural 
assessments. Blood was also collected at regular intervals to assess the pharmacokinetic profile of the drug. 
TAP was rapidly distributed and eliminated in rabbits. Apnoea did not occurred in any subject. Following 
surgery, there were very few observable signs of pain in four rabbits and all resumed normal activities within 
a few hours. In conclusion, this is the first study about the clinical effects and potential utility of TAP as an 
adjunct drug for anaesthesia and analgesia in the rabbit. However, further studies are still needed before its 
use in the veterinary clinical practice.
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duced gastrointestinal motility. Atypical opioid drugs, tra-
madol and tapentatol (TAP), have a lower affinity for the 
mu and/or kappa opioid receptors (thereby inducing less 
adverse effects) but their actions also inhibit serotonin and 
or norepinephrine reuptake, further contributing to the pain 
relief (6). 
Anecdotally, tramadol has been used in the clinical man-
agement of pain in rabbits, but the only published study to 
date (7) showed that an oral dose (11 mg/kg) resulted in 
plasma concentrations of the parent drug and its active me-
tabolite, O-desmethyltramadol, below levels considered an-
algesic in humans. The desired therapeutic plasma levels and 
the effective dose and dosing interval have not been estab-
lished in rabbits.
TAP is a novel opioid drug with features similar to 
tramadol which was launched on the European market 
for human use at the end of 2011. Several clinical stud-
ies in humans have shown that TAP provides analgesia of 
equal magnitude to classical opioids, morphine and oxy-
codone, but with lower adverse effects (8, 9). TAP could 
potentially overcome some of the disadvantages associated 
with tramadol, since TAP exists as a single stereoisomer 
and the parent compound is solely responsible for its phar-
macological activity. Accordingly, the relative contribu-
tions of the two mechanisms, mu opioid receptor (MOR) 
activation and noradrenalin reuptake inhibitor (NRI), do 
not vary during metabolic transformation. MOR agonism 
allows a reduction in spinal pain transmission as well as 
actions at supraspinal sites through descending projec-
tions that further reduce sensory transmission. The inhi-
bition of noradrenalin reuptake enhances the descending 
inhibition of pain likely via alpha 2 adrenoceptors (10). 
Furthermore, TAP does not affect (induce or inhibit) cy-
tochrome 450 (CYP450), a common metabolic pathway 
for opioid analgesics, while 5-hydroxytryptamine receptors 
(5HT) reuptake inhibition (which triggers adverse effects) 
is negligible (11). Due to a lack of serotonergic activity in 
tapentadol, pain facilitation via the descending transmis-
sion system is not enhanced, and the side effects caused by 
increased serotonin in the central and the enteric nervous 
systems (constipation, nausea, vomiting, and diarrhoea) are 
avoided (10). The aim of the present study was to assess 
the Phramacokinetic-Pharmacodynamic (PK-PD) profile 
of TAP intravenously administered to rabbits undergoing 
orchiectomy.
MATERIAL AND METHODS
Materials
Pure powder (>99.8% purity) of TAP hydrochloride was 
supplied by Bepharm (Shanghai, China). A pure solu-
tion of O-desmethyltramadol (M1), used as internal stan-
dard (IS), was purchased from LCG Promochem (Bologna, 
Italy). HPLC grade acetonitrile (ACN), dichlorometh-
ane (CH2Cl2), diethyl ether (Et2O), were purchased from 
Scharlau (Barcelona, Spain). Analytical grade acetic acid and 
sodium tetraborate decahydrate were obtained from BDH 
(Milan, Italy). HPLC grade water was obtained by distill-
ing deionised water produced by a Milli-Q Millipore Water 
System (Billerica, MA, USA). All the other reagents and 
materials were of analytical grade and supplied from com-
mercial sources.
Animals and experimental design
Seven male New Zealand White rabbits (Harlan, Udine, 
Italy) aged 12-16 months, with a mean bodyweight (BW) 
of 3.1 kg (2.8-3.5 kg), were used. The animals were housed in 
single cages in adjacent floor pens (1 m×1 m), under conven-
tional conditions of ventilation, temperature (18-22°C) and 
lighting (12 h light/day). They were acclimatised for a 2-week 
period prior to commencement of the study. During this pe-
riod the rabbits received food and water ad libitum. The rab-
bits were previously determined to be clinically healthy on 
physical examination, serum chemistry and haematological 
analyses. Animal care and handling was performed accord-
ing to the provision of the EC Council Directive 86/609 
EEC. The study was approved by the ethical committee for 
animal welfare of the University of Pisa (authorisation num-
ber 7920).
Rabbit surgical procedure
A 6-h period of pre-surgery fasting was applied. After 
clipping away hair, a local anaesthetic ointment (EMLA; 
AstraZeneca, Milan, Italy) was applied to both ears of 
each rabbit, in order to avoid discomfort associated with 
placement of two catheters. An IV polyurethane cath-
eter ( JelcoI.V. Catheter Radiopaque; Smiths Medical 
International Ltd, UK) was placed aseptically into the left 
external ear vein for the drug administration. The size of the 
catheter (22 G) was chosen to fit with the size of the vein 
of the animals. An extension (“T”-connector (Luer-lock) 
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with Bionector; Vygon, UK) was connected to the catheter 
to allow IV drug administration without touching or inter-
fering with the ear. The second catheter was inserted into 
the right median ear artery for the blood pressure measure-
ment. As a control and to ensure patency before adminis-
tration of TAP, the catheter was flushed with 2 mL saline 
0.9% (Viaflo, sodium chloride 0.9% w/v; Baxter, UK). TAP 
was prepared by dissolving pure TAP hydrochloride pow-
der into saline to give a 5 mg/mL solution, which was then 
passed through a 0.45 µm filter before being administered 
at a dose of 5 mg/kg (IV) over 2 min. The T0 min was taken 
at the end of drug administration (Figure 1). Five minutes 
later (T5 min), the rabbits were induced with sevoflurane 
(2.5% via face mask) and maintained at 3.5% (Sevorane, 
Abbott Laboratories, UK) using a calibrated ‘out-of-circuit’ 
vaporizer (Penlon Sigma Delta, Abingdon, UK) set at 2.5-
3.5%. At T5 min physiological parameters were measured 
before sevoflurane administration. During anaesthesia, 
Ringer’s lactate (10 mL/kg/h) was administered. The fluids 
were heated and the subjects were placed on a heating pad 
to avoid hypothermia.
Perioperative parameter evaluations
The following parameters were monitored during anaes-
thesia: heart rate (HR), electrocardiogram (ECG), invasive 
blood pressure (systolic arterial pressure (SAP)); diastolic ar-
terial pressure (DAP); mean arterial pressure (MAP), oxygen 
saturation (SpO2) with the probe positioned on the tongue, 
using a multiparametrical monitor (Mindray BeneView T5, 
China), respiratory rate (RR, via direct observation), right-
ing and palpebral reflex (absent, weak, strong), jaw tone and 
tongue retraction. The above parameters were monitored at 
Tbase (prior T0) on a fully conscious patient prior to TAP 
administration, T0 and then every 5 min for the duration of 
the surgical procedure. Periods where the animals were ex-
posed to surgical stimuli of a greater magnitude (T15 min: 
skin incision; T20 min: stretching funiculus; T25 min: first 
ligation testicle; T30 min: extending the second testicle; 
T35 min: tying the second testicle; T40 min: suturing skin) 
(Figure 1) were measured, recorded and studied.
At the end of the surgical procedure, sevoflurane was dis-
continued and the time until the return of righting reflex 
was recorded. Each rabbit was also administered enrofloxacin 
(Baytril, Bayer; Milan, Italy) at 10 mg/kg (SC) at the end of 
the procedure.
Analgesic rescue contingency plans included: increas-
ing sevoflurane concentration for reaction to the stimu-
lus on the skin (Backhaus positioning, skin incision) and 
an increase in sevoflurane concentration and/or infiltra-
tion of lidocaine into the spermatic cord for reaction to the 
visceral stimulus (stretch cord, tying testicles). However, 
Lidocaine was never used. Atropine, adrenaline, naloxone, 
intubation kit, and Ambu-bag were also available for other 
likely complications.
Post-surgical pain evaluation
After the return of righting reflex, rabbits were transferred 
to hospital cages and provided with food and water. Pain 
assessment was based on evaluation of ear position, face, 
abdomen, back and hind limbs (5). Briefly, the rabbits’ 
body was divided into 5 regions; (i) face (face, head and 
neck, but excluding the ears); (ii) ears (ears only) evaluated 
according to the grimace scale (12); (iii) abdomen; (iv) 
back; and (v) hindquarters, evaluated for pain-indicating 
behaviours and posture (e.g. back arching, skin twitches, 
muscle contracting, unusual position, etc. (13)). In addi-
tion, behavioural assessments (including reduced activity, 
excessively slow/fast response to external stimuli, increased 
aggression), as previously reported, were performed (13, 
14). These body and behavioural parameters, were scored 
separately from 0 to 10 according to the Numerical Rating 
Scale (NRS) of pain intensity (0 corresponds to the ab-
sence of pain and 10 maximum pain) in each subject for 
each observation time. Then all the scores were averaged 
Figure 1: Timing of drug administrations and pain evaluation.
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for each time point for each subject. The physiological as-
sessments (such as food and water intake, urination and 
defecation) were considered as “yes” or “no” (first food or 
water consumption or faeces production) and did not af-
fect the overall score but were considered important pa-
rameters to point out the rabbits’ wellbeing. These assess-
ments were carried out every hour for a total of 8 h (T2 
h – T10 h) after administration of TAP. Each evaluation 
was 10 minutes long. These evaluations were always car-
ried out using the same criteria and the same experienced 
observers, to reduce the bias.
Blood withdrawals for HPLC analysis
Blood samples (1 mL) were collected at 0.08, 0.25, 0.5, 0.75, 
1, 1.5, 2, 4, 6, 8, 10 and 24, h after administration of TAP, 
and placed in collection tubes containing lithium heparin. 
The blood samples were centrifuged at 1,000 g within 30 min 
of collection, and the harvested plasma was stored at -20°C 
until use (within 15 days of collection).
High performance liquid chromatography (HPLC)
The concentrations of TAP in plasma were evaluated using 
HPLC with fluorescence detector ( Jasco Europe, Modena, 
Italy), according to the method previously described by 
Giorgi et al. (15), with slight modifications. Briefly, the chro-
matographic separation assay was performed with a SunFire 
C18 analytical column (150×4.6 mm inner diameter, 5 µm 
particle size) (Waters, Milan, Italy) maintained at 25°C. The 
mobile phase consisted of ACN (A): 0.2% acetic acid (B) 
at a flow rate of 1 mL/min. Excitation and emission wave-
lengths were set at 273 and 298 nm, respectively. The linear 
gradient elution system was performed as follows; 5-95% A 
(0-20 min), 95-5% A (20-25 min) and finally 5% A isocrati-
cally (25-32 min). 
Pharmacokinetic evaluation
The pharmacokinetic calculations were carried out us-
ing WinNonLin v 5.3 (Pharsight, Sunnyvale, CA, USA). 
Maximum concentration (Cmax) of TAP in plasma, and the 
time required to reach Cmax (Tmax) were predicted from 
the data. The concentration at time 0 (C0) was estimated by 
back-extrapolating from the first two concentration values. 
The terminal rate constant (λ) was determined from the slope 
of the terminal phase of the plasma concentration curve that 
included a minimum of three points. Half-life of the terminal 
phase (T1/2 λz) was calculated using T1/2= 0.693⁄λ. The area 
under the concentration vs. time curve (AUC0-∞) was calcu-
lated using the linear trapezoidal rule. 
Changes in plasma concentration of TAP were evaluat-
ed using the standard non-compartmental analysis, and the 
relative pharmacokinetic parameters were determined using 
standard non-compartmental equations (16).
Statistical analysis
Graph-Pad Prism 4.0 (La Jolla, CA, USA) performed the 
statistical analysis of the parameters (Graph-Pad Software). 
Data were analysed for the normal distribution using 
the Kolmogorov-Smirnov test. The analysis of variance 
(ANOVA), with Tukey’s test as post hoc, was used to eval-
uate the likely differences between subjects. Additionally, 
ANOVA tests for repeated data with a test of Dunnett’s was 
carried out to evaluate differences in clinical parameters at 
Tbase and other recorded times for each subject. Values P 
<0.05 were considered significant.
RESULTS
Pharmacokinetic parameters
After TAP administration, concentrations were detectable in 
plasma for up to 4 h (Figure 2). In this period, the concen-
trations exceeded or were within the effective concentration 
range reported for humans (5-300 ng/mL). The clearance 
was rapid (2093 mL/h/Kg) and the volume of distribution 
was large (1522 mL/Kg). The mean pharmacokinetic values 
are reported in Table 1.
Pharmacodynamic parameters
The induction of anaesthesia was smooth and uncomplicat-
ed. At T0, all the subjects showed attenuation of righting 
and eyelid reflexes, tongue retraction and jaw tone becoming 
completely absent at T5 min.
The mean HR was almost constant in all subjects (Figure 
3). Significant increases in this parameter were recorded in 
relation to surgical stimuli at T20 min and T30 min in all 
subjects except one. The sevoflurane concentration was in-
creased to 4-4.5% and dropped down to 3.5% as soon the 
HR decreased. All rabbits showed polypnoea at Tbase and 
T0. The RR decreased significantly to T5 min and was con-
stant from T10 min to T40 min (Figure 4). Only two sub-
jects showed a slight increase in RR in relation to surgical 
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stimuli. Apnoea was not recorded during the procedure. The 
percentage of SpO2 was stable between 97% and 100% in all 
subjects throughout orchiectomy.
There was evidence of an increase in SAP between 
T0 and T5 min (Figure 5a). Significant reductions in this 
parameter were recorded for the whole surgical period. A 
continuous slight, but non-significant decrease in DAP 
was reported (Figure 5b). This parameter was constant 
during the surgical stimuli. MAP increased at T5 min in 
all subjects, except one (Figure 5c). However, this param-
eter did not change significantly in relation to surgical 
stimuli.
All the rabbits regained consciousness quickly and 
quietly; reappearance of the righting reflex was recorded 
between 5 and 15 min after discontinuation of sevoflu-
rane, and sedation disappeared within 30 min. The assess-
ment of post-surgical pain was carried out using the NRS 
(Table 2). Four rabbits were scored with the lightest value 
of pain after 2 h from the TAP administration. After the 
3 h evaluation point, animals were assessed as not affected 
by pain. In line to these evaluations, most of the rabbits 
ate, drank, urinated and defecated at the first evaluation 
point (2 h), while all the animals did so by 4 h after TAP 
administration.
Table 1: Main pharmacokinetics parameters of TAP following single 
IV administration at 5 mg/kg in New Zealand White rabbits (n=7).
Parameters Mean SD CV%
R2 0.990 0.009 0.9
λz (1/h) 1.44 0.38 26.6
Τ1/2 λz (h) 0.52 0.17 31.8
Cmax (ng/mL) 4257 1247 29.3
C0 (ng/mL) 6260 2737 43.7
AUC0-∞ (h ng/mL) 2446 411 16.8
VZ (mL/Kg) 1522 400 26.3
CL (mL/h/Kg) 2093 345 16.5
AUMC0-∞ (h h ng/mL) 1739 355 20.4
MRT (h) 0.71 0.11 15.6
R2 = correlation coefficient; λz = terminal phase rate constant; Τ1/2λz = 
terminal half-life; Cmax = peak plasma concentration; C0 = calculated 
concentration at T0; AUC0-∞ = area under the plasma concentration-
time curve extrapolated to infinity; VZ = volume of distribution; CL = 
clearance; AUMC0-∞ = area under the first moment curve from zero to 
infinity; MRT = mean resident time.
Figure 2: Plasma concentration vs. time mean curve of TAP, following 
single IV administration at 5 mg/kg in New Zealand rabbits (n=7). 
Bars represent the standard deviation.
Figure 3: Mean beats/min vs. time curve (-○-) following single IV 
administration at 5 mg/kg in New Zealand rabbits (n=7). Mean Tbase 
value is indicated by ●. Bars represent the SD values. * Significantly 
different from T0; § significantly different from T5 (P<0.05).
Figure 4: Mean respiratory rate vs. time curve (-○-) following single IV 
administration at 5 mg/kg in New Zealand rabbits (n=7). Mean Tbase 
value is indicated by ●. Bars represent the SD values. * Significantly 
different from T0; § significantly different from T5 (P<0.05).
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DISCUSSION
The pharmacokinetic analysis showed that TAP, when ad-
ministered via an IV route in rabbits at the dose of 5 mg/
kg, was rapidly and widely distributed to tissues with a 
distribution volume of 1.5 L/kg. This value was lower com-
pared to that observed both in rats (10.4 L/kg) adminis-
tered with similar dose (17) and dogs (9.0 L/kg) adminis-
tered with half the dose (6). In contrast, the half-life (T1/2 
λz) was similar to the values reported in rats (17) and dogs 
(6). TAP showed rapid elimination with a clearance value 
seven times lower than in rats (17) and four times lower 
than in dogs (6, 17), which may reflect species differences 
in metabolism. This is not a pure PK study because TAP 
was administered with sevofluorane but, although some 
parameters could be slightly modified, it is unlikely that 
sevofluorane co-administration may extensively affect the 
PK of the opioid (18).
In humans, the minimum effective concentration (MEC) 
range is between 5-300 ng/mL (Prof. Rolf Terlinden, per-
sonal communication, 2007). A following study reported as 
MEC, a more accurate value of 0.67 mM/L, equivalent to 
148 ng/mL (19). The extrapolation of the MEC value from 
human to rabbits is not ideal and caution should be used. In 
the present study, rabbits were also administered with sevo-
flurane that could have affected the effectiveness of TAP. 
However, the behavioural and physiological assessments 
showed that TAP was effective in providing post surgical 
analgesia. The mean plasma concentration of TAP after 2 h 
(first evaluation time of post surgical pain) was 260 ng/mL 
and 16 ng/mL at 4 h (which was also the limit of detection 
for analysis in plasma (10 ng/mL)). These low concentration 
values might suggest the rabbit is an animal species more 
susceptible to TAP (as already reported for other opioids 
(20)) than humans, although further pure PK/PD studies in 
rabbits are required to confirm this.
The reason why orchiectomy was chosen as the surgical 
procedure in order to assess the efficacy of TAP as an an-
algesic, was because castration is the most frequent surgi-
cal procedure in the rabbit in our Veterinary school. TAP 
Figure 5: a) Mean systolic arterial pressure vs. time curve (-○-) 
following single IV administration at 5 mg/kg in New Zealand 
rabbits (n=7). Mean Tbase value is indicated by ●. Bars represent the 
SD values. * Significantly different from T0; § significantly different 
from T5 (P<0.05); b) Mean diastolic arterial pressure vs. time curve 
(-○-) following single IV administration at 5 mg/kg in New Zealand 
rabbits (n=7). Mean Tbase value is indicated by ●. Bars represent the 
SD values; c) Mean arterial pressure vs. time curve (-○-) following 
single IV administration at 5 mg/kg in New Zealand rabbits (n=7). 
Mean Tbase value is indicated by ●. Bars represent the SD values. * 
Significantly different from T0 (P<0.05).
Table 2: Individual pain assesment by NRS (number).
Rabbits
Time (h) A B C D E F G
2 la 1a 1ab 0 1 0b 0ab
3 0 0b 0 0b 0b 0 0
4 0b 0 0 0a 0a 0a 0
5 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0
7 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0
a1st food consumption; b1st feaces production.
a) b)
c)
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provided good intra-surgery analgesia. However, to assess 
properly the pain relief produced by TAP a control rabbit 
group should have been used, but was not possible for ethi-
cal reasons. To avoid this concern, an historical compari-
son with the institution’s standard anaesthetic protocol in 
rabbits (ketamine (15 mg/kg) and medetomidine (0.5 mg/
kg) IM) for routine surgery (21), such as orchiectomy, was 
performed. The clinical records of 19 rabbits over the last 2 
years showed that the combination of TAP and sevoflurane 
resulted in a very rapid and smooth recovery (15-30 min), 
in contrast to ketamine/medetomidine (86-120 min (22)). 
If the effects of medetomidine was reversed by the specific 
antagonist, righting reflex returned within 5 min, but se-
dation lasted for over 1 h (23). The righting reflex ranged 
within 5 and 15 min after the sevoflurane discontinuation 
in the present study, but sedation also disappeared rapidly 
(within 30 min).
The increase in HR was not accompanied by an increase 
in MAP during the surgical procedure. Typically, following 
a pain stimulus, an early increase in MAP followed by an in-
crease of the RR and HR is expected. Hence, the observed 
variation in HR may be related to an unstable or light an-
aesthesia regimen. Moreover, the stretching of the gonads 
can cause sympathetic stimulation, which accounts for the 
increase in HR (24). A combination of the present anaes-
thetic protocol with a sedative drug (e.g. alpha-2-agonist), 
could evoke a deeper anaesthesia, although further studies to 
support this hypothesis are required. The increase in MAP 
at T5 min could be explained by the mechanism of action of 
the drug. TAP is an inhibitor of norepinephrine reuptake and 
might stimulate a sympathetic response (25).
Respiratory depression and apnoea are the most common 
complications encountered with classical more potent opi-
oids in humans (26) and animals (24). In the present study 
apnoea did not occurred in any subject. This was very sig-
nificant for rabbits since they are anatomically difficult to 
intubate and frequently exhibit trauma, laryngeal spasm and 
tracheal injury following intubation (27). Given the moder-
ate affinity of TAP at the mu opioid receptor and the opioid-
sparing effect of TAP’s norepinephrine reuptake inhibitor 
component, it seems logical that TAP would produce fewer 
opioid-related side effects than classical MOR agonists, such 
as morphine. In contrast, classical opioid drugs, in addition to 
limited efficacy, induce hypotension, respiratory depression 
and prolonged recovery time in rabbits (24).
There does not appear to be a validated pain measure-
ment scale based on objective parameters published for 
the rabbit. As such, assessment of pain in rabbits is there-
fore more subjective than in other domestic species where 
validated pain scales are currently used. Recent studies 
(5,13) reported an insensitivity to pain assessment in rab-
bits when facial responses only were evaluated, while re-
sponses in areas such as the ears, abdomen, back and hind 
limbs were considered more significant. In the present 
study, pain assessment was based on evaluation of areas 
described by Leach et al. (5,13), in addition to physiologi-
cal assessments (such as food and water intake, urination 
and defecation) and behavioural assessments (such as re-
duced activity, slow/fast response to external stimuli, in-
creased aggression), as previously reported by Flecknell 
(14). Food and water intake, considered with urine and 
stool production, did not affect the NRS but were con-
sidered physiological changes that assist pain assessment 
in the rabbit and would not take place if the subjects were 
experiencing pain (28,29).
At T2 h, four subjects showed the slightest sign of pain 
(body’s and behavioural) and they resumed normal activi-
ties (food intake, urination, defecation) within a few hours. 
These observations suggested that TAP provided sufficient 
post-surgery analgesia in each subject. It should be noted that 
sevoflurane has no specific analgesic effect, which is therefore 
only provided by TAP. Moreover, the institution’s routine 
anaesthetic protocol for rabbits (ketamine-demetomidine) 
usually required additional analgesia (multimodal approach) 
during the postoperative recovery. This is also in agreement 
with other previous evaluations (21). 
CONCLUSIONS
This is the first PK/PD study of TAP in rabbits. TAP proved 
an effective analgesic agent in this species on the basis of 
the parameters used as pain markers in the present study. 
TAP elicited a good analgesic plane that resulted in a bet-
ter post-operative course with a more rapid recovery of pa-
tients, compared to the institution’s standard anaesthetic 
protocol for rabbits (ketamine-medetomidine). No com-
plications occurred, particularly apnoea or reduced blood 
pressure. Further studies are required before TAP can be 
used routinely in veterinary clinical practice, but these pre-
liminary findings can pave the way for its use as a useful 
analgesic in rabbits.
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